FDA publishes final Q&A on biosimilar development and the BPCI Act

INICIO/Políticas y legislación | Posted 15/10/2021 post-comment0 Post your comment

The US Food and Drug Administration (FDA) has published its final guidance document on questions and answers related to biosimilar development and the Biologics Price Competition and Innovation Act of 2009 (BCPI Act).

Question-Fimea-V15E29

In September 2021, FDA published a revised version of its guidance document ‘Questions and Answers on Biosimilar Development and the BPCI Act – Guidance for Industry’.

The final guidance is part of a series of documents developed by FDA to facilitate the development of biosimilars and covers questions on biosimilarity and interchangeability, submitting a biologics license application (BLA), and exclusivity.

The finalized document is the second revision of a document first released in 2015. The first revision was issued in 2020 [1]. The finalized document includes revisions and additional questions (five questions have been added and seven updated).

The updated questions remain largely the same as in previous versions with minor changes, while the new questions address:
• Sponsors responsibilities related to paediatric assessments for proposed biosimilars
• The information needed to support post-approval manufacturing changes
• That sponsors may not seek approval for a biosimilar with a different route of administration, dosage form, or strength than the reference product
• That biosimilars may not be approved for conditions of use that have not previously been approved for the reference product
• That sponsors should provide data and information to support the approval of a biosimilar for an indication that is still covered by unexpired orphan exclusivity (although FDA will not approve such an indication until the orphan exclusivity expires)

The finalized guidance can be read in full at the FDA website.

In May 2021, the agency released its final guidance on BCS-based biowaivers, providing recommendations to support the waiver of the in vivo bioequivalence study requirement for certain drug products [2].

Related articles
FDA updates generics guidance due to COVID-19 pandemic

FDA approves first interchangeable insulin glargine biosimilar

LATIN AMERICAN FORUM

The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View this week’s headline article: Posible colaboración biotecnológica entre India y Colombia

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

LATIN AMERICAN FORUM

Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de esta semana: Posible colaboración biotecnológica entre India y Colombia

Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 

 
References
1. GaBI Online - Generics and Biosimilars Initiative. FDA issues Q & A on biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Oct 15]. Available from: www.gabionline.net/guidelines/FDA-issues-Q-A-on-biosimilars
2. GaBI Online - Generics and Biosimilars Initiative. FDA issues final guidance on BCS-based biowaivers [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Oct 15]. Available from: www.gabionline.net/guidelines/fda-issues-final-guidance-on-bcs-based-biowaivers

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

Source: US FDA

comment icon Comments (0)
Post your comment
Related content
Generic ‘skinny’ labelling under threat in the US
Label prescription drugs
INICIO/Políticas y legislación Posted 05/11/2021
Lawsuits and US$450 million payout for price fixing and delayed generics entry
34 AA010660
INICIO/Políticas y legislación Posted 29/10/2021
FDA publishes final Q&A on biosimilar development and the BPCI Act
Question-Fimea-V15E29
INICIO/Políticas y legislación Posted 15/10/2021
FDA voices concerns around drug patents and competition
Patent 1 V13E17
INICIO/Políticas y legislación Posted 08/10/2021
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010